COMP <GO>
SCL vs EPC // EV/EBITDA & P/E VALUATION
Stepan Company (NYSE) VS. Edgewell Personal Care Company (NYSE) • 15-METRIC TALLY: SCL 7
— EPC 4
▲ EV/EBITDA & P/E VALUATION LEADER: SCL
LAST: $69.99 (+2.31%) • MKT CAP: $1.59B
valuation
9.8x
LAST: $28.57 (+3.25%) • MKT CAP: $1.32B
valuation
29.4x
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (SCL VS. EPC)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | SCL | EPC | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 11.60% | 41.60% | -30.00 | EPC | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 4.30% | 2.50% | +1.80 | SCL | /roic <GO> |
| EV/EBITDA & P/E Valuation ACTIVE | 9.8x | 29.4x | -19.60 | SCL | /valuation <GO> |
| Free Cash Flow Yield | 1.59% | 8.99% | -7.40 | EPC | /fcf-yield <GO> |
| Operating Margin | 3.40% | 4.30% | -0.90 | EPC | /operating-margins <GO> |
| Net Profit Margin | 2.00% | 1.10% | +0.90 | SCL | /net-margins <GO> |
| Revenue Growth (YoY) | 7.00% | -1.30% | +8.30 | SCL | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 2.20% | 2.23% | -0.03 | EPC | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | — | 1.58 | — | TIE | /balance-sheet <GO> |
| Piotroski F-Score Quality | 7/9 | 7/9 | 0.00 | TIE | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 76.2 | 55.6 | +20.64 | SCL | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | 31.5x | 48.2x | -16.70 | SCL | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $1.59B | $1.32B | $274.3M | SCL | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | SCL REV | EPC REV | SCL GROSS % | EPC GROSS % | SCL FCF | EPC FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $2.33B | $2.22B | 11.6% | 41.6% | $25.4M | $118.4M |
| FY 2024 | $2.18B | $2.25B | 12.5% | 42.4% | $39.3M | -$231.0M |
| FY 2023 | $2.33B | $2.25B | — | — | $174.9M | -$216.1M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
SCL // BETA —
EPC // BETA —